The REVLIRIT CLL5 AGMT Study - a Phase I/II Trial Combining Fludarabine/Rituximab with Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis.
- Resource Type
- Abstract
- Source
- In
Blood 20 November 2009 114(22):3453-3453 - Subject
- Language
- ISSN
- 0006-4971